World Library  
Flag as Inappropriate
Email this Article

Ns-2359

Article Id: WHEBN0022602885
Reproduction Date:

Title: Ns-2359  
Author: World Heritage Encyclopedia
Language: English
Subject: Serotonin–norepinephrine–dopamine reuptake inhibitor, 2α-(Propanoyl)-3β-(2-(6-methoxynaphthyl))-tropane, RTI-353, FE-β-CPPIT, FP-β-CPPIT
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Ns-2359

NS-2359
Systematic (IUPAC) name
(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane
Clinical data
Legal status
?
Identifiers
ATC code None
PubChem
Chemical data
Formula C15H19Cl2NO 
Mol. mass 300.223 g/mol
 YesY   

NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[2] phase II having been completed in 2007.[3] A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.[4]

Another scientific article on NS-2359 was recently (2011) published.[5] As can be seen from reading the abstract to the citation, the compound failed to perform in clinical trials for the treatment of depression.

See also

References

  1. ^ a b "NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression". 
  2. ^ Wilens, T. E.; Klint, T.; Adler, L.; West, S.; Wesnes, K.; Graff, O.; Mikkelsen, B. (2008). "A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD". Behavioral and Brain Functions 4: 24.  
  3. ^ http://clinicaltrials.gov/ct2/show/NCT00467428
  4. ^ http://clinicaltrials.gov/ct2/show/NCT00032916
  5. ^ Learned, S.; Graff, O.; Roychowdhury, S.; Moate, R.; Krishnan, K. R.; Archer, G.; Modell, J. G.; Alexander, R.; Zamuner, S.; Lavergne, A.; Evoniuk, G.; Ratti, E. (2011). "Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: Two randomized, placebo- and active-controlled clinical trials". Journal of Psychopharmacology 26 (5): 653–662.  



This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.